Domestic institutional brokerage firm Motilal Oswal Financial Services has officially initiated research coverage on Aster DM Quality Care, issuing an assertive 'Buy' rating on the newly merged healthcare major with a base-case target price of ₹910 per share, indicating a 20 percent upside potential. Following the high-profile corporate merger between Aster DM Healthcare and Quality Care India (QCIL), the consolidated enterprise has established itself as one of the country's preeminent healthcare networks. The operational entity commands an expansive footprint comprising 39 state-of-the-art hospitals and approximately 10,600 operational beds spread across 28 key metropolitan and Tier-1 cities, creating substantial operational scale and bargaining leverage across pharmaceutical procurement, medical device sourcing, and specialized clinical infrastructure.

Bull Case Projects 46% Upside as Bed Capacity Targets 15,000 Milestone by FY2030

Motilal Oswal's equity research note outlines an aggressive bull-case projection forecasting an upside potential of up to 46 percent from current levels. This optimistic trajectory is predicated on rapid post-merger operational synergy realization, accelerated capacity rollout, and an increase in bed inventory to more than 15,000 operational beds by FY2030 through a balanced mix of brownfield additions, greenfield clinical setups, and capital-efficient asset-light management partnerships. The bullish thesis assumes an upward trajectory in overall bed occupancy rates, higher Average Revenue Per Occupied Bed (ARPOB), and accelerated margin contribution from high-margin tertiary and quaternary medical procedures, supplemented by double-digit expansion across medical value travel (inbound medical tourism).

Bearish Valuation Floor at ₹700, Key Structural Risks, and Strong Analyst Consensus

Balancing the upside projections, Motilal Oswal established a bear-case downside floor of ₹700 per share, implying an 8 percent retracement based on a 12-month forward EBITDA of ₹2,490 crore valued at 25 times EV/EBITDA. This cautious scenario models potential headwinds such as prolonged integration lags between Aster and QCIL, slower execution on planned brownfield bed additions, suboptimal occupancy levels, and persistent post-merger overhead expenses, alongside sector-wide challenges including clinical price caps and regulatory interventions. On Monday, Aster DM Quality Care shares traded lower by 1.4 percent at ₹748.45, preserving a strong year-to-date advance of roughly 23 percent. Across the institutional landscape, consensus remains decisively bullish, with 13 of the 15 analysts tracking the company maintaining a 'Buy' recommendation, alongside one 'Hold' and one 'Sell' rating.